Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Refractory Leukemia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Refractory Leukemia - Pipeline Review, H1 2015', provides an overview of the Refractory Leukemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Refractory Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Leukemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Refractory Leukemia Overview 6 Therapeutics Development 7 Pipeline Products for Refractory Leukemia - Overview 7 Pipeline Products for Refractory Leukemia - Comparative Analysis 8 Refractory Leukemia - Therapeutics under Development by Companies 9 Refractory Leukemia - Pipeline Products Glance 10 Clinical Stage Products 10 Refractory Leukemia - Products under Development by Companies 11 Refractory Leukemia - Companies Involved in Therapeutics Development 12 Bayer AG 12 Colby Pharmaceutical Company 13 Galileo Research s.r.l. 14 Novartis AG 15 XBiotech USA, Inc. 16 Refractory Leukemia - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 BAY-1143572 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 CA-18C3 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 JVRS-100 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 TALL-104 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 trametinib dimethyl sulfoxide - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Refractory Leukemia - Recent Pipeline Updates 35 Refractory Leukemia - Dormant Projects 38 Refractory Leukemia - Dormant Projects 38 Refractory Leukemia - Discontinued Products 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 40 Disclaimer 41
List of Tables
Number of Products under Development for Refractory Leukemia, H1 2015 7 Number of Products under Development for Refractory Leukemia - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 10 Products under Development by Companies, H1 2015 11 Refractory Leukemia - Pipeline by Bayer AG, H1 2015 12 Refractory Leukemia - Pipeline by Colby Pharmaceutical Company, H1 2015 13 Refractory Leukemia - Pipeline by Galileo Research s.r.l., H1 2015 14 Refractory Leukemia - Pipeline by Novartis AG, H1 2015 15 Refractory Leukemia - Pipeline by XBiotech USA, Inc., H1 2015 16 Assessment by Monotherapy Products, H1 2015 17 Number of Products by Stage and Target, H1 2015 19 Number of Products by Stage and Mechanism of Action, H1 2015 21 Number of Products by Stage and Route of Administration, H1 2015 23 Number of Products by Stage and Molecule Type, H1 2015 25 Refractory Leukemia Therapeutics - Recent Pipeline Updates, H1 2015 35 Refractory Leukemia - Dormant Projects, H1 2015 38 Refractory Leukemia - Discontinued Products, H1 2015 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.